Zevra Therapeutics (ZVRA) reported a Q4 net loss Tuesday of $0.67 per diluted share, wider than a loss of $0.51 a year earlier.

Analysts polled by FactSet expected a loss of $0.38.

Net revenue for the quarter ended Dec. 31 was $12 million, down from $13.2 million a year earlier.

Analysts surveyed by FactSet expected $8.9 million.

Shares of Zevra Therapeutics were down over 3% in after-hours trading.